Oestrogen treatment of adolescent tall girls; short term side effects

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S170-S173 ◽  
Author(s):  
OLAV TRYGSTAD
Keyword(s):  
Side Effects ◽  
Idiopathic Scoliosis ◽  
Final Height ◽  
Psychosocial Problems ◽  
Short Term ◽  
Oestrogen Treatment ◽  
Duration Of Therapy ◽  
Tall Girls ◽  
The Mean ◽  
Ethinyl Oestradiol

Abstract In 1980-1985 680 preadolescent tall girls were treated with pharmacological doses of oestrogen to reduce final height. Indications for the therapy were predicted final height >+2.5 SD (180.75 cm), idiopathic scoliosis, and psychosocial problems. Until 1976 141 girls were given diethyl stilboestrol 5 mg daily. By advice of Prader this was then replaced by ethinyl oestradiol and a progestin was given on days 5-10 each month. The mean duration of therapy was close to 2 years. The observed short-term unwanted effects were due to the pharmacological actions of the drugs, (11 girls had galactorrhoea at the end of therapy; no pituitary prolactionoma was observed) or events happening by chance.

Oestrogen treatment of constitutionally tall girls with 0.1 mg/day ethinyl oestradiol

1988 ◽  
Vol 147 (1) ◽  
pp. 59-63 ◽  
Author(s):  
O. Bartsch ◽  
B. Weschke ◽  
B. Weber
Keyword(s):  
Oestrogen Treatment ◽  
Tall Girls ◽  
Ethinyl Oestradiol

Propranolol in the Management of Infantile Hemangiomas: Clinical Response and Predictors

2012 ◽  
Vol 16 (3) ◽  
pp. 169-173 ◽  
Author(s):  
Alexandra Balma-Mena ◽  
Ajith Chakkittakandiyil ◽  
Miriam Weinstein ◽  
Perla Lansang ◽  
Nhung Ho ◽  
...  
Keyword(s):  
Cohort Study ◽  
Side Effects ◽  
Clinical Response ◽  
Retrospective Cohort ◽  
Analogue Scale ◽  
Optimal Dose ◽  
Duration Of Therapy ◽  
Predictors Of Response ◽  
Percent Improvement ◽  
The Mean

Background: Recent data suggest that propranolol is an effective treatment for infantile hemangiomas (IHs). Data on the optimal dose, duration of therapy, and predictors of response are currently lacking. Objective: To assess the clinical response to and predictors of propranolol use in the treatment of IH. Methods: Retrospective cohort study of 44 patients. Two independent assessors evaluated improvement by comparing serial digital photographs using a 100 mm visual analogue scale (VAS), where 5 mm change represented 10% change in the size or appearance of the IH. Results: Propranolol was started at a mean age of 7.8 (SD 8.21) months and was used for 7.3 (SD 4.8) months before weaning. The mean percent improvement compared to baseline (as measured by the VAS) was 78% (SD 23%). Minor adverse events were noted in 32% of patients. The most significant predictor of regrowth after weaning was a IH > 5 cm in size ( p = .017). Conclusions: Propranolol is effective in IH, but the side effects and the possibility of regrowth should be considered.

Impact of different doses of ethinyl oestradiol on reduction of final height in constitutionally tall girls

1994 ◽  
Vol 153 (11) ◽  
pp. 797-801 ◽  
Author(s):  
E. E. Joss ◽  
J. Zeuner ◽  
R. P. Zurbrügg ◽  
P. E. Mullis
Keyword(s):  
Final Height ◽  
Tall Girls ◽  
Different Doses ◽  
Ethinyl Oestradiol

Intravenous infusion of bombesin reduces food intake in humans

1993 ◽  
Vol 264 (2) ◽  
pp. R350-R354 ◽  
Author(s):  
N. E. Muurahainen ◽  
H. R. Kissileff ◽  
F. X. Pi-Sunyer
Keyword(s):  
Side Effects ◽  
Food Intake ◽  
Test Meal ◽  
Intravenous Infusion ◽  
Category Scale ◽  
Point Scale ◽  
Short Term ◽  
The Mean ◽  
First Time ◽  
Slow Intravenous Infusion

Infusion of bombesin into healthy young men at two dosages (1.33 and 4.0 ng.kg-1.min-1) resulted in a significant 135-g reduction in intake of a yogurt and fruit blend, compared with saline infusions, at the higher dose, but only a 20-g (nonsignificant) reduction at the lower dose. There were no overt side effects, although half of the subjects reported a slightly elevated (mean elevation = 0.5 on a 1-5 category scale) sick sensation when receiving bombesin at the higher dose, but not when receiving saline. At the higher dose, the mean palatability of the test meal was reduced by 0.5 units on a nine-point scale of liking. This study demonstrates for the first time in humans that a slow intravenous infusion of bombesin can decrease spontaneous food intake when infused at the rate of 4 ng.kg-1.min-1 beginning at the onset of a meal. These results confirm that the short-term satiety effect of peripherally administered bombesin previously reported in animals can be obtained in humans.

Studies of the factors modulating antidiuretic hormone excretion in man in response to the osmolar stimulus: effects of oestrogen and angiotensin II

1983 ◽  
Vol 104 (3) ◽  
pp. 295-302 ◽  
Author(s):  
Michel B. Vallotton ◽  
Ulrich Merkelbach ◽  
Rolf C. Gaillard
Keyword(s):  
Angiotensin Ii ◽  
Antidiuretic Hormone ◽  
Hypertonic Saline ◽  
Plasma Renin ◽  
Electrolyte Balance ◽  
Renin Substrate ◽  
Oestrogen Treatment ◽  
Significant Difference ◽  
The Mean ◽  
Ethinyl Oestradiol

Abstract. The aim of this study was to assess the influence of hormones known to regulate fluid and electrolyte balance on the release of antidiuretic hormone induced by raising serum osmolality. The stimulus provoked by the infusion of a 2.5% NaCl solution induces an increase of urinary [arginine-8]vasopressin from 1.12 to 2.64 ng/h in men and from 1.65 to 7.27 ng/h in women as has been previously reported. These results were compared to those obtained in males infused with angiotensin II (All) before and during a hypertonic sodium load and in males infused with hypertonic saline on the fourth day of administration of ethinyl-oestradiol. During the combined infusion of All and then hypertonic saline, the mean hourly urinary excretion of AVP increased from 2.8 to 5.67 ng/h. Within each group the increase of urinary AVP was highly significant. The rise of urinary AVP during All infusion was significantly different from the rise observed both in untreated males and untreated females, lying in between. The mean hourly excretion rate of AVP increased before and after hypertonic saline loading from 2.65 to 5.3 ng/h in males pre-treated with ethinyl-oestradiol. The significant difference observed between males and females is reduced when males treated with oestrogen were compared to female subjects. In each group plasma renin activity decreased to low values during the salt-loading test. During oestrogen treatment PRA and plasma renin substrate rose, while urinary aldosterone remained almost unchanged. We conclude that All stimulates the release of AVP in males and potentiates the response of AVP to the osmolar stimulus, and that oestrogen potentiates in man the release of AVP in response to the osmolar stimulus. This oestrogenic effect may account for the observed sex difference.

Effects of luteinizing hormone-releasing hormone (LRH) upon bioactive and immunoreactive serum LH in patients with Turner's syndrome before and after oestrogen treatment

1985 ◽  
Vol 109 (3) ◽  
pp. 304-308 ◽  
Author(s):  
Marco Francesco Celani ◽  
Vanna Montanini ◽  
Paolo Marrama
Keyword(s):  
Biologically Active ◽  
Delayed Response ◽  
Turner's Syndrome ◽  
Turner’S Syndrome ◽  
Oestrogen Treatment ◽  
Serum Lh ◽  
Before And After ◽  
The Mean ◽  
Ethinyl Oestradiol

Abstract. One daily dose of 0.05 mg ethinyl oestradiol was administered to 5 patients with Turner's syndrome (mean age ± sem = 16.4 ± 0.7 years) for 10 days. The effects of acute stimulation with luteinizing hormonereleasing hormone (LRH) (0.1 mg iv) on biologically active and immunoreactive LH were analysed before therapy and at the end of oestrogen treatment. Bioactive LH (BIO-LH) was measured by a sensitive and specific in vitro bioassay based upon testosterone production by mechanically dispersed mouse Leydig cell preparations. Immunoreactive LH (RIA-LH) was evaluated by a double antibody RIA method. Prior to oestrogen treatment, LRH induced a prompt rise in BIO-LH and RIA-LH levels, which reached peak values at 30 and 45 min, respectively. After oestrogen treatment, a delayed response (with peak values at 120 min) was observed for both BIO-LH and RIA-LH. Before oestrogen treatment, the mean bioactivity to immunoreactivity (B/I) ratio of LRH-stimulated LH showed a significant decrease from basal values (P < 0.05). In contrast, after ethinyl oestradiol administration the mean LH B/I ratio increased significantly from basal values in response to LRH (P < 0.05). The mean relative maximum response (Δ%) for BIO-LH was significantly higher (P < 0.05) in oestrogen-treated than in untreated patients, whereas the mean BIO-LH Δ area was significantly lower in the former group (P < 0.01). Similarly, oestrogens decreased significantly the mean RIA-LH Δ area (P < 0.05), whereas they did not affect significantly the mean RIA-LH Δ%. The results further emphasize that oestrogens may change the quality of circulating LH.

Age Distribution, Side Effects and Co-Occurring Diagnoses, and Duration of Treatment of Multiple Myeloma Patients Receiving Bortezomib or Lenalidomide in Community Oncology Clinics

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5738-5738
Author(s):  
Jennifer Reichert ◽  
Jeffrey Patton
Keyword(s):  
Multiple Myeloma ◽  
Side Effects ◽  
Blood Cells ◽  
White Blood Cells ◽  
Age Distribution ◽  
The United States ◽  
Nausea And Vomiting ◽  
Duration Of Therapy ◽  
Community Oncology ◽  
The Mean

Abstract Introduction: The introduction of novel therapies has revolutionized the treatment of multiple myeloma in the last 20 years. Outcomes vary significantly by age with younger patients experiencing longer survival than older patients. The majority of cancer patients in the United States receive treatment in community oncology practices, as opposed to university hospital settings. RainTree Analytics maintains a unique database of electronic medical record (EMR) data from RainTree Oncology member community oncology practices. We sought to understand the treatment patterns and patient demographics of multiple myeloma patients in community oncology practices. Methods: A search of the RainTree Analytics database was conducted for patients with an ICD-9 code of 203.0-203.02 (multiple myeloma). 2771 patients who received treatment for multiple myeloma between January 2, 2012 and July 9, 2014 were identified. Of these 2022 had received either bortezomib or lenalidomide, or both. We compared the characteristics of patients who had received prescriptions for bortezomib but not lenalidomide (N = 551) or lenalidomide but not bortezomib (N = 699), the two most frequently prescribed multiple myeloma therapies, excluding melphalan and dexamethasone. Results: Most patients who received either bortezomib or lenalidomide, but not both, were over 60. The age distribution of these two populations is provided in Table 1. Table 1. Age Distribution of Bortezomib and Lenalidomide Patients AGE Bortezomib Patient Count (%) Lenalidomide Patient Count (%) 21-30 1 (0.18) 1 (0.14) 31-40 4 (0.73) 2 (0.29) 41-50 17 (3.09) 38 (5.44) 51-60 65 (11.80) 107 (15.31) 61-70 147 (26.68) 220 (31.47) 70+ 317 (57.53) 331 (47.35) Total 551 699 Side effects and co-occurring diagnoses listed as ICD-9 codes in the EMR were analysed. The most frequently co-occurring diagnoses reported in the EMR in bortezomib and lenalidomide patients were anemias, nausea and vomiting, and diseases of white blood cells (Figure 1). Anemias were reported at approximately the same frequency in bortezomib and lenalidomide patients, 9.07% and 8.73%, respectively. Nausea and vomiting (ICD-9 codes 787.01-787.2) were reported more frequently in bortezomib patients than in lenalidomide patients, 9.26% and 3.29%, respectively, but diseases of white blood cells (1.63% (bortezomib) and 5.29% (lenalidomide)) and sepsis or complications due to vascular devices (0.54% (bortezomib) and 4.58% (lenalidomide)) were reported more frequently in lenalidomide patients. Figure 1. Side Effects and Co-occurring Diagnoses in Patients Taking Bortezomib and Lenalidomide Figure 1. Side Effects and Co-occurring Diagnoses in Patients Taking Bortezomib and Lenalidomide Bortezomib and lenalidomide duration of therapy were analysed for patients who had received at least one refill for the therapy. The mean duration of therapy for bortezomib and lenalidomide was 203 and 250 days, respectively (Table 2). The mean number of prescriptions written for bortezomib was greater than the mean number of prescriptions written for lenalidomide, as would be expected for the methods of delivery of the two therapies. Table 2. Duration of Bortezomib or Lenalidomide Therapy Bortezomib Lenalidomide Mean Number of Prescriptions Written 20 9 Duration of Therapy Mean 203 250 Median 142 163 Minimum 33 30 Maximum 903 908 Standard Deviation 178 224 Conclusions: The age distributions and duration of therapy for bortezomib and lenalidomide were similar for the two therapies, however, there were significant differences in co-occurring diagnoses reported by ICD-9 in the EMR. Further study is warranted to investigate which of these co-occurring diagnoses are associated with pre-existing patient characteristics and which may be the results of differences in therapies. Disclosures Reichert: RainTree Oncology Services: Employment. Patton:Pfizer: Consultancy; Johnsone & Johnson: Consultancy; Tasaro: Consultancy; Bristol Myers Squibb: Consultancy; Lilly: Consultancy; Genentech: Consultancy; Amgen: Consultancy; RainTree Oncology Services: Employment; Astellas: Consultancy.

P12.08 Efficacy of trazodone slow release in insomnia associated with high-dose steroid therapy in neuro-oncological patients

2021 ◽  
Vol 23 (Supplement_2) ◽  
pp. ii32-ii32
Author(s):  
A Botturi ◽  
P Gaviani ◽  
V Redaelli ◽  
G Simonetti ◽  
C Lucchiari ◽  
...  
Keyword(s):  
Side Effects ◽  
Common Side Effect ◽  
Future Research ◽  
High Dose ◽  
Short Term ◽  
Drug Interference ◽  
The Third ◽  
Oncological Patients ◽  
Hamilton Anxiety Scale ◽  
The Mean

Abstract BACKGROUND Insomnia linked to therapeutical intake of intravenous (IV) megadoses of steroid (Mgds, 8–16 mg) is a common side effect in neuro-oncology patients. Hypno-inducing drugs (IP) and Benzodiazepines (BDZ) can provoke drug interference and daytime sedation. Trazodone (Trz) is an atypical antidepressant with poor liver metabolism; it has moderate histamine-1 (H1) receptor antagonism and possesses some anxiolytic and hypnotic properties. We tested the use of the Trz retard (RP) formulation as a hypnotic drug in patients undergoing a therapeutic regimen with IV Mgds. To evaluate anxiety and side effects. MATERIAL AND METHODS 10 patients (6 females and 4 males) admitted to the Neuro-oncology Department of the Neurological Institute “Carlo Besta” treated with Mgds IV. The average age was 55 years and the mean HAM-A score was 25. Instruments included the Hamilton Anxiety Scale (HAM-A), the Clinical Global Impression (CGI), and the Pittsburgh Sleep Quality Index (PSQI). Trz RP was administered at a dosage of 25-50-75 mg/day in the evening. RESULTS All 10 patients reported improved hypnotic profiles within the third day of Trz RP administration. Four patients improved on the first day. Reduction of the HAM-A score was found on the third day. No adverse events (epilepsy, daytime sedation, incontinence) were observed in 3 weeks. CONCLUSIONS Trz RP proved to have a swift beneficial effect on sleep and anxiety without side effects in the short term. Trz may be preferred to IP and BDZ in patients receiving IV Mgds, considering the lack of daytime sedation and the reduced pharmacological inference. Larger samples will enable future research to better describe the characteristics and the indication of Trz.

Impact of different doses of ethinyl oestradiol on reduction of final height in constitutionally tall girls

1994 ◽  
Vol 153 (11) ◽  
pp. 797-801
Author(s):  
E. E. Joss ◽  
J. Zeuner ◽  
R. P. Zurbr�gg ◽  
P. E. Mullis
Keyword(s):  
Final Height ◽  
Tall Girls ◽  
Different Doses ◽  
Ethinyl Oestradiol

Severe Drooling and Treatment With Botulinum Toxin

2012 ◽  
Vol 21 (1) ◽  
pp. 15-21
Author(s):  
Merete Bakke ◽  
Allan Bardow ◽  
Eigild Møller
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Health Risk ◽  
Flow Rate ◽  
Clinical Evidence ◽  
Acetylcholine Release ◽  
Psychosocial Problems ◽  
Rate Reduction ◽  
Local Inhibition ◽  
Surgical Treatments

Severe drooling is associated with discomfort and psychosocial problems and may constitute a health risk. A variety of different surgical and non-surgical treatments have been used to diminish drooling, some of them with little or uncertain effect and others more effective but irreversible or with side effects. Based on clinical evidence, injection with botulinum toxin (BTX) into the parotid and submandibular glands is a useful treatment option, because it is local, reversible, and with few side effects, although it has to be repeated. The mechanism of BTX is a local inhibition of acetylcholine release, which diminishes receptor-coupled secretion and results in a flow rate reduction of 25–50% for 2–7 months.

Sign in / Sign up

Export Citation Format

Share Document